Early diagnosis of breast cancer is the key to survival. Yet mammograms can catch the disease too late and carry an unacceptably high rate of false positives. Additionally, millions of women worldwide have little or no access to hospital screenings. For example, in India there are only 16 mammography machines, serving 650 million women. This is a massive unmet need.

Our idea was to combine the flexibility of wearables with the science of breast cell metabolism and the technology of predictive analytics to create a revolutionary wearable that detects breast cancer — earlier and more accurately than mammograms. Additionally, the device will potentially reduce unnecessary false positives by over 50%.

This is an idea that gives women control of their breast health, and brings the power of early detection to millions of women worldwide, even those with little access to hospital screening. Just imagine how many lives will be saved.

Our idea was to combine the flexibility of wearables with the science of breast cell metabolism and the technology of predictive analytics to create a revolutionary wearable that detects breast cancer—earlier and more accurately than mammograms. The goal was to overcome the challenges of current breast cancer screening—including late detection, high rates of false positives, and inaccuracy in dense breast tissue. This device empowers women worldwide to take control of their own breast health, with an accurate, convenient, and affordable breast self-exam that can be done anywhere.

We’ve earned three patents, raised $6.5 million over the last 5 years, and completed over 5 years of clinical trials with leading research institutions at a cost exceeding $15 million. The results have been stunning. We achieved 83% accuracy in detecting tumors, equal to mammograms, and 30% better in dense breast tissue. We’re ready to take the iTBra worldwide.

Having earned three patents, invested over $15 million, and raised $6.5 million over the last 5 years, we’re ready to launch the iTBra to markets around the world. With 500,000 anticipated orders this year, the iTBra will reach more women at risk of breast cancer than ever before. And our manufacturer is prepared to release millions of iTBra sets on an annual basis. Additionally, retail partnerships (including Lululemon and Uniqlo) will provide the iTBra to consumers globally. We also expect to achieve the largest breast cancer database in the world by the end of 2018, providing a game-changer in the field of cancer research.

With the documented limitation of mammography, and the minimal access to these machines in many parts of the world, we are positioning the iTBra to replace mammography as the gold standard of breast cancer screening in the next 5 years.